NCT07850336Not yet recruiting
Pancreatic Endoscopic Ultrasound-guided RadioFrequency for Inoperable Carcinoma Treatment
Pancreatic Endoscopic Ultrasound-guided RadioFrequency for Inoperable Carcinoma Treatment (PERFECT Study)
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate whether endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) affects survival in patients with inoperable pancreatic carcinoma. By using a prospective single-arm design with historical controls, this study aims to generate clinically relevant data while minimizing the number of patients exposed to experimental treatment. The findings may support future integration of EUS-RFA into standard care for this high-need patient population.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- First submitted
- 17 Sept 2026
- Start date
- 1 Oct 2026
- Primary completion date
- Dec 2030
- Lead sponsor
- Bojan Kovacevic
- Diseases
- Pancreatic cancer
- NCT number
- NCT07850336
What you commit to
- Study type: Interventional
- Planned participants: 56
- From 1 Oct 2026 to the primary completion date, Dec 2030
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior local ablative treatment interfering with outcome
Other illness
- Metastatic disease
- Active untreated infection or pancreatitis
Lab values
- Uncorrected coagulopathy (INR ≥1.5 or thrombocyte count \< 50 mia/L)
Other
- Altered anatomy or interposition of major vessels precluding safe EUS-RFA
- Life expectancy \<3 months
Who the study is looking for
- Adult habile patients with a signed informed consent
- Histologically confirmed pancreatic carcinoma ≤5 cm in largest diameter
- ECOG performance status 0-2
- Patients not eligible for curative-intended surgical treatment due to:
- Advanced (unresectable) disease, or Unsuitability for surgery due to comorbidities or poor performance status, or Patient preference to decline surgery
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.